会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 84. 发明申请
    • NOVEL N-3 IMMUNORESOLVENTS: STRUCTURES AND ACTIONS
    • 新型N-3免疫球蛋白:结构和作用
    • WO2014193652A3
    • 2015-02-26
    • PCT/US2014037969
    • 2014-05-14
    • BRIGHAM & WOMENS HOSPITAL
    • SERHAN CHARLES NDALLI JESMOND
    • A61K31/202
    • C07C57/03C07D303/38
    • The invention describes novel mono-hydroxy, di-hydroxy and tri-hydroxy docosapentaenoic acid (DPA) analogues, their preparation, isolation, identification, purification and uses thereof. Resolution of inflammation is now held to be an active process where autacoids promote homeostasis. Using functional-metabololipidbmics and in vivo systems, endogenous n-3 docosapentaenoic (DP A) acid is converted during inflammation-resolution in mice and by human leukocytes to novel n-3 products congenerous to D-series resolvins (Rv), protectins (PD) and maresins (MaR), termed specialized pro-resolving mediators (SPM). The new n-3 DPA structures include 7,8,17-trihydroxy-9,11,13,15E, 19Zdocosapentaenoic acid (RvD1n_3 DPA), 7, 14-dihydroxy-8, 10, 12, 16Z, 19Z-docosapentaenoic acid (MaR1n_3 DPA) and related bioactive products.
    • 本发明描述了新的单羟基,二羟基和三羟基二十二碳烯酸(DPA)类似物,其制备,分离,鉴定,纯化和用途。 炎症的解决方案现在被认为是一种活性过程,其中自发性促进促进体内平衡。 使用功能代谢组合物和体内系统,内源性n-3二十二碳烯酸(DPA)酸在小鼠和人类白细胞的炎症分解过程中被转化成与D系列溶解素(Rv),保护素(PD)一致的新型n-3产物 )和马林(MaR),称为专门解析介质(SPM)。 新的n-3DPA结构包括7,8,17-三羟基-9,11,13,15E,19Z二十碳五烯酸(RvD1n_3DPA),7,14-二羟基-8,10,12,16Z,19Z-二十二碳五烯酸( MaR1n_3 DPA)及相关生物活性产品。